In a report released today, Stefan Quenneville from Echelon Wealth Partners reiterated a Buy rating on Valeo Pharma (VPHIF – Research Report), with a price target of C$1.00. The company’s shares closed yesterday at $0.43.
According to TipRanks, Quenneville is an analyst with an average return of -9.8% and a 32.93% success rate. Quenneville covers the Healthcare sector, focusing on stocks such as Valeo Pharma, Antibe Therapeutics, and Cognetivity Neurosciences.
Valeo Pharma has an analyst consensus of Moderate Buy, with a price target consensus of $0.73.
See the top stocks recommended by analysts >>
The company has a one-year high of $0.67 and a one-year low of $0.15. Currently, Valeo Pharma has an average volume of 2,988.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Valeo Pharma Inc a Canadian specialty pharmaceutical company focused on acquiring either through acquisitions, in-licensing or similar arrangements. Its current markets its product Synacthen Depot which is a synthetic ACTH product that is used in conditions where the production of natural cortisol and other hormones is desired.
